OPTN OptiNose Inc.

8.47
+0.24  (+3%)
Previous Close 8.23
Open 8.28
Price To Book 7.92
Market Cap 352,196,711
Shares 41,581,666
Volume 264,491
Short Ratio
Av. Daily Volume 247,949
Stock charts supplied by TradingView

NewsSee all news

  1. Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference

    YARDLEY, Pa., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive

  2. Optinose Announces Pricing of Public Offering of Common Stock

    YARDLEY, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an

  3. Optinose Announces Proposed Public Offering of Common Stock

    YARDLEY, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it and certain

  4. Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

    XHANCE net revenue grew 30% to $8.7 million from second to third quarter 2019 XHANCE prescriptions increased 27% from second to third quarter 2019 Company expects XHANCE net revenues for 2019 to be in the

  5. Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019

    YARDLEY, Pa., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 commencement of enrolment announced December 10, 2018.
XHANCE
Chronic sinusitis
Approval announced September 18, 2017 (prior to IPO).
XHANCE
Nasal polyps
Commencement of enrolment announced December 10, 2018.
XHANCE
Nasal polyps - pediatric

Latest News

  1. Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference

    YARDLEY, Pa., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive

  2. Optinose Announces Pricing of Public Offering of Common Stock

    YARDLEY, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an

  3. Optinose Announces Proposed Public Offering of Common Stock

    YARDLEY, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it and certain

  4. Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

    XHANCE net revenue grew 30% to $8.7 million from second to third quarter 2019 XHANCE prescriptions increased 27% from second to third quarter 2019 Company expects XHANCE net revenues for 2019 to be in the

  5. Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019

    YARDLEY, Pa., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will

  6. Optinose Appoints Michael Richardson to New Position of Vice President, Business Development

    YARDLEY, Pa., Oct. 04, 2019 (GLOBE NEWSWIRE) --  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported the creation of a new

  7. Optinose to Present at the 2019 Cantor Global Healthcare Conference

    YARDLEY, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive

  8. Currax™ Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail®

    MORRISTOWN, N.J., Sept. 26, 2019 /PRNewswire/ -- Currax Pharmaceuticals LLC, a specialty biopharmaceutical company with both Branded and generic business units, announced today a deal whereby Currax obtained patent

  9. OptiNose Announces License Agreement Related to ONZETRA XSAIL

    YARDLEY, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OptiNose, Inc. (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the

  10. Former BlackRock Senior Portfolio Manager Shinda Bickham Joins Aura's Capital Markets Team

    Bickham brings more than 15 years of credit investing and asset management experience to help Aura expand its social bond platform Aura, a CDFI-certified fintech company that uses technology to disrupt predatory

  11. Optinose Announces Departure of Chief Commercial Officer

    YARDLEY, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the departure of its

  12. Optinose Announces $150 Million Debt Financing from Pharmakon

    YARDLEY, Pa., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported that it has entered